lumasiran
Sign in to saveAlso known as ALN-GO1
Lumasiran, sold under the brand name Oxlumo, is a medication for the treatment of primary hyperoxaluria type 1 (PH1).
Clinical Trials
10 registered- PHASE3COMPLETEDA Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1Alnylam Pharmaceuticals · NCT03681184
- APPROVED_FOR_MARKETINGExpanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1Alnylam Pharmaceuticals · NCT04125472
- ACTIVE_NOT_RECRUITINGBONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)Alnylam Pharmaceuticals · NCT04982393
- PHASE3COMPLETEDA Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1Alnylam Pharmaceuticals · NCT03905694
- PHASE3COMPLETEDA Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1Alnylam Pharmaceuticals · NCT04152200
- PHASE2COMPLETEDAn Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1Alnylam Pharmaceuticals · NCT03350451
Wikidata facts
- Instance of
- small interfering RNA
Show 1 more fact
- Commons category
- Lumasiran
via Wikidata · CC0
~4 min read
Encyclopedic overview
6 sectionsContents
- Medical uses
- History
- Society and culture
- Legal status
- References
- External links
Lumasiran, sold under the brand name Oxlumo, is a medication for the treatment of primary hyperoxaluria type 1 (PH1).
The most common side effects include injection site reactions and abdominal pain.
Excerpted from Wikipedia’s “lumasiran” article, available under the CC BY-SA 4.0 licence.